公开(公告)号：US20170081332A1

公开(公告)日：2017-03-23

申请号：US15311025

申请日：2015-05-15

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takahiro SUGIMOTO ,  Kenichiro SHIMOKAWA ,  Takuto KOJIMA ,  Hiroki SAKAMOTO ,  Ikuo FUJIMORI ,  Minoru NAKAMURA ,  Masami YAMADA ,  Masataka MURAKAMI ,  Makoto KAMATA ,  Shinkichi SUZUKI

IPC: C07D487/04 ,  C07D471/04

CPC classification number: C07D487/04 ,  A61K31/437 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/501 ,  A61K31/519 ,  C07D471/04

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as medicaments such as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like, and the like. The present invention relates to a compound represented by the formula (I) wherein ring A is an optionally substituted 5- or 6-membered ring; R is a C1-6 alkyl group substituted by 1 to 5 halogen atoms; and X is —CH═ or —N═, or a salt thereof.

公开(公告)号：US20240109874A1

公开(公告)日：2024-04-04

申请号：US18504741

申请日：2023-11-08

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masami YAMADA ,  Shinkichi SUZUKI ,  Takahiro SUGIMOTO ,  Minoru NAKAMURA ,  Hiroki SAKAMOTO ,  Makoto KAMATA

IPC: C07D405/14 ,  A61K31/045 ,  A61K31/13 ,  A61K31/325 ,  A61K31/4035 ,  A61K31/4155 ,  A61K31/4406 ,  A61K31/4439 ,  A61K31/445 ,  A61K31/55 ,  C07D209/46 ,  C07D401/06 ,  C07D401/10 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04

CPC classification number: C07D405/14 ,  A61K31/045 ,  A61K31/13 ,  A61K31/325 ,  A61K31/4035 ,  A61K31/4155 ,  A61K31/4406 ,  A61K31/4439 ,  A61K31/445 ,  A61K31/55 ,  C07D209/46 ,  C07D401/06 ,  C07D401/10 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D471/04

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like.
The present invention relates to a compound represented by the formula (I) or a salt thereof.




wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US20220411413A1

公开(公告)日：2022-12-29

申请号：US17872680

申请日：2022-07-25

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masami YAMADA ,  Shinkichi SUZUKI ,  Takahiro SUGIMOTO ,  Minoru NAKAMURA ,  Hiroki SAKAMOTO ,  Makoto KAMATA

IPC: C07D405/14 ,  C07D209/46 ,  C07D401/10 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D401/06 ,  C07D405/04 ,  A61K31/4035 ,  A61K31/4155 ,  A61K31/4439 ,  A61K31/13 ,  A61K31/325 ,  A61K31/445 ,  A61K31/55 ,  A61K31/045 ,  A61K31/4406

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like.
The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US20190241547A1

公开(公告)日：2019-08-08

申请号：US16209349

申请日：2018-12-04

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masami YAMADA ,  Shinkichi SUZUKI ,  Takahiro SUGIMOTO ,  Minoru NAKAMURA ,  Hiroki SAKAMOTO ,  Makoto KAMATA

IPC: C07D405/14 ,  C07D209/46 ,  A61K31/4439 ,  A61K31/4406 ,  A61K31/045 ,  A61K31/55 ,  A61K31/445 ,  A61K31/325 ,  A61K31/13 ,  C07D401/06 ,  A61K31/4155 ,  A61K31/4035 ,  C07D403/10 ,  C07D403/04 ,  C07D401/14 ,  C07D401/10 ,  C07D405/04

CPC classification number: C07D405/14 ,  A61K31/045 ,  A61K31/13 ,  A61K31/325 ,  A61K31/4035 ,  A61K31/4155 ,  A61K31/4406 ,  A61K31/4439 ,  A61K31/445 ,  A61K31/55 ,  C07D209/46 ,  C07D401/06 ,  C07D401/10 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D471/04

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like.The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US20170100373A1

公开(公告)日：2017-04-13

申请号：US15388834

申请日：2016-12-22

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masami YAMADA ,  Shinkichi SUZUKI ,  Takahiro SUGIMOTO ,  Minoru NAKAMURA ,  Hiroki SAKAMOTO ,  Makoto KAMATA

IPC: A61K31/4035

CPC classification number: C07D405/14 ,  A61K31/045 ,  A61K31/13 ,  A61K31/325 ,  A61K31/4035 ,  A61K31/4155 ,  A61K31/4406 ,  A61K31/4439 ,  A61K31/445 ,  A61K31/55 ,  C07D209/46 ,  C07D401/06 ,  C07D401/10 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D471/04

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like.The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US20170027921A1

公开(公告)日：2017-02-02

申请号：US15291769

申请日：2016-10-12

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masami YAMADA ,  Shinkichi SUZUKI ,  Takahiro SUGIMOTO ,  Minoru NAKAMURA ,  Hiroki SAKAMOTO ,  Makoto KAMATA

IPC: A61K31/4439 ,  A61K31/4155 ,  A61K31/4035

CPC classification number: C07D405/14 ,  A61K31/045 ,  A61K31/13 ,  A61K31/325 ,  A61K31/4035 ,  A61K31/4155 ,  A61K31/4406 ,  A61K31/4439 ,  A61K31/445 ,  A61K31/55 ,  C07D209/46 ,  C07D401/06 ,  C07D401/10 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D471/04

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like.The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.

Abstract translation: 其中每个符号如说明书中所述或其盐。

公开(公告)号：US20160376244A1

公开(公告)日：2016-12-29

申请号：US15190642

申请日：2016-06-23

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takahiro SUGIMOTO ,  Shinkichi SUZUKI ,  Hiroki SAKAMOTO ,  Masami YAMADA ,  Minoru NAKAMURA ,  Makoto KAMATA ,  Kenichiro SHIMOKAWA ,  Masaki OGINO ,  Eiji KIMURA ,  Masataka MURAKAMI ,  Jinichi YONEMORI ,  Takuto KOJIMA

IPC: C07D265/22 ,  C07D413/06 ,  C07D491/107 ,  C07D413/04 ,  C07F7/02 ,  C07D471/04 ,  C07D413/14 ,  C07D413/10

CPC classification number: C07D413/14 ,  A61P25/28 ,  C07B2200/07 ,  C07D265/22 ,  C07D413/04 ,  C07D413/06 ,  C07D413/10 ,  C07D417/06 ,  C07D417/10 ,  C07D471/04 ,  C07D491/107 ,  C07F7/02 ,  C07F7/0814

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.

Abstract translation: 其中每个符号如所附的说明中所定义。

公开(公告)号：US20230322683A1

公开(公告)日：2023-10-12

申请号：US17766400

申请日：2020-10-15

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masashi TOYOFUKU ,  Yoshiteru ITO ,  Marilena PIRA ,  Takahiro SUGIMOTO

IPC: C07D231/56 ,  C07D405/12 ,  C07D471/04 ,  C07D498/04 ,  A61P25/28

CPC classification number: C07D231/56 ,  C07D405/12 ,  C07D471/04 ,  C07D498/04 ,  A61P25/28

Abstract: The present invention provides a compound having a cell degeneration inhibitory action, particularly a motor neuron degeneration inhibitory action, which is useful as an agent for the prophylaxis or treatment of motor neuron diseases (e.g., amyotrophic lateral sclerosis, progressive bulbar paralysis, progressive muscular atrophy, primary lateral sclerosis, progressive pseudobulbar paralysis, spinal muscular atrophy, Parkinson's disease, Lewy body dementia, multiple-system atrophy, Friedreich's ataxia) and the like.
The present invention relates to a compound represented by the formula (I):




wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US20220017514A1

公开(公告)日：2022-01-20

申请号：US17413473

申请日：2019-12-11

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuichi KAJITA ,  Yuhei MIYANOHANA ,  Tatsuki KOIKE ,  Yasutaka HOASHI ,  Yasushi HATTORI ,  Norihito TOKUNAGA ,  Tsuneo ODA ,  Tohru MIYAZAKI ,  Dilhumar UYGHUR ,  Yoshiteru ITO ,  Kohei TAKEUCHI ,  Keisuke IMAMURA ,  Takahiro SUGIMOTO ,  Koichiro FUKUDA ,  Yasuhisa KOHARA ,  Rei OKAMOTO ,  Taiichi OHRA ,  Naoki MIYAMOTO ,  Yoshito TERAO ,  Masanori KAWASAKI

IPC: C07D471/04 ,  C07D231/56 ,  C07D277/64 ,  C07D215/38 ,  C07D401/14

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US20200207734A1

公开(公告)日：2020-07-02

申请号：US16633960

申请日：2018-08-02

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuichi KAJITA ,  Satoshi MIKAMI ,  Yuhei MIYANOHANA ,  Tatsuki KOIKE ,  Masaki DAINI ,  Norio OYABU ,  Masaki OGINO ,  Kohei TAKEUCHI ,  Yoshiteru ITO ,  Norihito TOKUNAGA ,  Takahiro SUGIMOTO ,  Tohru MIYAZAKI ,  Tsuneo ODA ,  Yasutaka HOASHI ,  Yasushi HATTORI ,  Keisuke IMAMURA

IPC: C07D401/06 ,  C07D211/56 ,  C07D401/10 ,  C07D405/10 ,  C07D207/14 ,  C07D417/06 ,  C07D405/12 ,  C07D409/10 ,  C07D413/06 ,  C07D401/14 ,  C07D205/04 ,  A61P25/26

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.